Radiopharmaceutical developer Navidea Biopharmaceuticals has posted mixed results for its third quarter (end-September 30).
Total revenue for the quarter was $231,000, compared with $224,000 in the third quarter of 2017. The company's net loss for the quarter was $3.8 million, compared with a net loss of $1.4 million in the same quarter of 2017.
Total revenue for the first nine months of 2018 was $1.1 million, compared with $1.4 million for the same period in 2017. Net loss for the first nine months of the year was $13 million, compared with net income of $79 million in 2017.
